Vanessa Yan
Psychiatric/Mental Health · Anaheim, CANPI 1790458883
Payments from drug & device makers
Across 910 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$10K
- AbbVie$3K
- Johnson & Johnson$2K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- plus $7K from 22 others
What the payments were for
- Consulting fees$3301%
- Speaking & faculty fees$5,46321%
- Travel & lodging$1,0654%
- Food & beverage$19,09073%
- Education$2471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 148 | $10,022 |
| AbbVie | 111 | $2,839 |
| Johnson & Johnson | 71 | $2,005 |
| Neurocrine Biosciences, Inc. | 58 | $1,564 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 109 | $1,431 |
| Alkermes, Inc. | 40 | $1,218 |
| Otsuka America Pharmaceutical, Inc. | 36 | $1,130 |
| Lundbeck LLC | 43 | $727 |
| Axsome Therapeutics, Inc. | 30 | $724 |
| Ironshore Pharmaceuticals Inc. | 40 | $676 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $591 |
| Idorsia Pharmaceuticals US Inc | 31 | $501 |
| Indivior Inc. | 29 | $489 |
| Corium, LLC | 24 | $447 |
| Noven Therapeutics, LLC | 20 | $428 |
| Almatica Pharma LLC | 15 | $301 |
| Sunovion Pharmaceuticals Inc. | 18 | $293 |
| Supernus Pharmaceuticals, Inc. | 21 | $196 |
| E.r. Squibb & Sons, L.L.C. | 8 | $193 |
| Avanir Pharmaceuticals, Inc. | 1 | $125 |
| Acadia Pharmaceuticals Inc | 1 | $118 |
| Vanda Pharmaceuticals Inc. | 3 | $72 |
| Noven Pharmaceuticals, Inc. | 2 | $39 |
| Tris Pharma Inc | 1 | $21 |
| Novo Nordisk | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $9 |
| Brainsway USA Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$6,919
- LYBALVI$1,338
- VRAYLAR$871
- INVEGA SUSTENNA$524
- INVEGA TRINZA$524
- INGREZZA$358
- REXULTI$351
- AUSTEDO$263
- NUEDEXTA$125
- SPRAVATO$125
- JORNAY PM$125
- UZEDY$125
- Auvelity$121
- ABILIFY MAINTENA$121
- QUVIVIQ$121
- CAPLYTA$119
- NUPLAZID$118
How this compares
$26,194 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 39 | $478,612 |
| VraylarCariprazine Hcl | 28 | $43,742 |
| Abilify MaintenaAripiprazole | 12 | $33,270 |
| CaplytaLumateperone Tosylate | 15 | $24,735 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $21,575 |
| Lurasidone Hcl | 20 | $18,734 |
| TrintellixVortioxetine Hydrobromide | 18 | $15,925 |
| Aripiprazole OdtAripiprazole | 11 | $6,638 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $3,192 |
| Bupropion XlBupropion Hcl | 44 | $2,897 |
| Paliperidone ErPaliperidone | 12 | $2,828 |
| Aripiprazole | 23 | $2,320 |
| Temazepam | 27 | $2,154 |
| Ramelteon | 25 | $1,687 |
| Quetiapine Fumarate | 106 | $1,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $10,022 | $478,61239 claims |
| AbbVieVraylar | $2,839 | $43,74228 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,130 | $33,27012 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,431 | $24,73515 claims |
| Alkermes, Inc.Lybalvi | $1,218 | $21,57512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $591 | $15,92518 claims |
| Almatica Pharma LLCSertraline Hcl | $301 | $59884 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Anaheim
- Samantha PerkinsAnaheim$49K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- David OhIrvine$72K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.